» Articles » PMID: 11760786

Expression, Specificity and Immunotherapy Potential of Prostate-associated Genes in Murine Cell Lines

Overview
Journal World J Urol
Specialty Urology
Date 2002 Jan 5
PMID 11760786
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

The TRAMP-C1 (C1) and TRAMP-C2 (C2) cell lines were derived from a prostate tumor that arose in a mouse from the transgenic adenocarcinoma mouse prostate (TRAMP) model. However, their similarity to primary prostate tumors and therefore their usefulness in immunotherapy studies has not been clearly defined. We showed using RT-PCR that these cell lines exhibited a variety of prostate-specific genes expressed by human prostate tumors that may be used as tumor-associated antigens for immunotherapy. Interestingly, several of these genes are also expressed in cell lines that are not prostatic in origin. The prostate cell lines were also shown to grow in an androgen-independent manner, to be capable of expressing MHC class I and to be susceptible to specific lysis by cytotoxic T lymphocytes. Therefore, these cell lines will provide us with the ability to evaluate immune responses to and tolerance of prostate-specific protein peptides in an animal model.

Citing Articles

Oncogenic mechanisms of missense mutations in prostate carcinogenesis.

Cardoso M, Maia S, Paulo P, Teixeira M Oncoscience. 2017; 3(9-10):288-296.

PMID: 28050579 PMC: 5116946. DOI: 10.18632/oncoscience.322.


Oncolytic herpes simplex virus armed with xenogeneic homologue of prostatic acid phosphatase enhances antitumor efficacy in prostate cancer.

Castelo-Branco P, Passer B, Buhrman J, Antoszczyk S, Marinelli M, Zaupa C Gene Ther. 2010; 17(6):805-10.

PMID: 20220784 PMC: 3243306. DOI: 10.1038/gt.2010.20.


Prostate stem cell antigen DNA vaccination breaks tolerance to self-antigen and inhibits prostate cancer growth.

Ahmad S, Casey G, Sweeney P, Tangney M, OSullivan G Mol Ther. 2009; 17(6):1101-8.

PMID: 19337234 PMC: 2835175. DOI: 10.1038/mt.2009.66.


Cutting edge: permissive MHC class II allele changes the pattern of antitumor immune response resulting in failure of tumor rejection.

Klyushnenkova E, Kouiavskaia D, Berard C, Alexander R J Immunol. 2009; 182(3):1242-6.

PMID: 19155468 PMC: 2743899. DOI: 10.4049/jimmunol.182.3.1242.


Obstructing shedding of the immunostimulatory MHC class I chain-related gene B prevents tumor formation.

Wu J, Atteridge C, Wang X, Seya T, Plymate S Clin Cancer Res. 2009; 15(2):632-40.

PMID: 19147769 PMC: 2775521. DOI: 10.1158/1078-0432.CCR-08-1305.